"The potential to deliver 'one-shot cures' is one of the most attractive aspects of gene therapy, genetically engineered cell therapy and gene editing," the analysts wrote. (CBC)The report reminded investors that curing a disease might be bad for business, and that sparked headlines last week. "If you're a drug company with shareholders, your main priority is the return to shareholders." - Aidan HollisUniversity of Calgary economist Aidan Hollis said cures are still good business. It's a formula that calculates how long a drug extends life along with the quality of that time.

Source: CBC News April 20, 2018 16:41 UTC